Fundraising Fox

Hilltop Bio

Norwood, US · Founded 2018 · 21 employees on LinkedIn · 6 known investors

Hilltop Bio develops bioscaffold and therapeutic products for veterinary use, including wound care, joint health, soft tissue repair, and ophthalmic solutions for equine and small animal patients.

BiotechHealthtechMedical Devices

Founders & leadership

MWMark Williams
Mark WilliamsinVice President Of Business Development2018–2025
ADAmanda Drobnis
Amanda DrobnisinCEO/Co-Founder

Board

JM
Jessica McLearBoard director
AW
Alan WatsonBoard director
DB
Denise BeversBoard director

Investors · 6

Band of AngelsSilicon Valley
Beacon AngelsBoston · $50K – $400K
Launchpad Venture GroupBoston · $8M – $10M
RevUp CapitalBoston · $350K – $400K
Walnut Venture AssociatesWellesley
Golden SeedsreportedFlushing · $250K – $2M

Reported raises · per SEC filings

Form D private placements

$7.8M disclosed across 5 rounds · 2019–2024

▶$5.3MraisedMar 2025 · 73 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark WilliamsExecutive Officer, Director
  • Jessica McLearDirector
  • Alan WatsonDirector
  • Denise BeversDirector
  • Amanda DrobnisExecutive Officer, Director
Offering amount
$5.5M
Amount sold
$5.3M
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$723.5KraisedApr 2023 · 42 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Amanda DrobnisExecutive Officer, Director
  • Alan WatsonDirector
  • Denise BeaversDirector
  • Mark WilliamsDirector
  • Jessica McLearDirector
Offering amount
$1M
Amount sold
$723.5K
First sale
Dec 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$866.3KraisedOct 2021 · 67 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark WilliamsExecutive Officer, Director
  • Jessica McLearDirector
  • Denise BeversDirector
  • Alan WatsonDirector
  • Amanda DrobnisExecutive Officer, Director
Offering amount
$1.4M
Amount sold
$866.3K
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$149.7KraisedMay 2020 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Denise BeversDirector
  • Jill WittelsDirector
  • Amanda DrobnisExecutive Officer, Director
  • Jessica McLearDirector
  • Mark WilliamsExecutive Officer, Director
Offering amount
$450K
Amount sold
$149.7K
First sale
May 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$750.9KraisedJul 2019 · 48 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark WilliamsExecutive Officer, Director
Offering amount
$1M
Amount sold
$750.9K
First sale
Jul 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Hilltop Biosciences Secures Funding to Accelerate Leadership in Biotech Innovation and Commercial Growtheinpresswire.com · Jan 2025Hilltop Biosciences Closes New Round of Funding – The Horsethehorse.com · Mar 2022

Frequently asked questions

What does Hilltop Bio do?
Hilltop Bio develops bioscaffold and therapeutic products for veterinary use, including wound care, joint health, soft tissue repair, and ophthalmic solutions for equine and small animal patients.
Who are Hilltop Bio's investors?
Hilltop Bio's investors include Band of Angels, Beacon Angels, Launchpad Venture Group, RevUp Capital, Walnut Venture Associates, Golden Seeds.
How much funding has Hilltop Bio raised?
Hilltop Bio has disclosed $7.8M raised across 5 rounds.
Where is Hilltop Bio headquartered?
Hilltop Bio is headquartered in Norwood, US.